第九版胸膜间皮瘤肿瘤-淋巴结-转移分类病理T调整的外部验证。

IF 3.5 3区 医学 Q2 ONCOLOGY
Frontiers in Oncology Pub Date : 2025-09-10 eCollection Date: 2025-01-01 DOI:10.3389/fonc.2025.1557097
Zheng Liu, Jingsheng Cai, Yun Li, Wenhan Weng
{"title":"第九版胸膜间皮瘤肿瘤-淋巴结-转移分类病理T调整的外部验证。","authors":"Zheng Liu, Jingsheng Cai, Yun Li, Wenhan Weng","doi":"10.3389/fonc.2025.1557097","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In the ninth edition pleural mesothelioma (PM) pathological (p) T staging, patients with fissural invasion are upgraded from T1 to T2. This study aimed to externally validate this staging modification.</p><p><strong>Methods: </strong>Resected pT1/2 PM patients were selected. The Kaplan-Meier method was applied to assess survival differences, and propensity score matching was utilized to balance baseline characteristics. Univariable and multivariable Cox analyses were conducted to determine prognostic factors. Multiple model parameters were used to evaluate the performance of the ninth and eighth edition pT staging in distinguishing between T1 and T2 patients.</p><p><strong>Results: </strong>A total of 818 eligible patients were included, among whom 325 initially classified as T1 were reclassified as T2 due to fissural invasion, resulting in 57 patients remaining with pT1 disease. Survival analyses demonstrated that both before and after matching, the ninth edition T staging effectively differentiated between T1 and T2 patients, whereas the eighth edition did not perform as satisfactorily in distinguishing between the groups. Cox regression analyses further confirmed that the ninth edition T staging was a strong prognostic factor, whereas the eighth edition T staging was not prognostic. Lastly, model parameter results indicated that the ninth edition T staging performed better in distinguishing between T1 and T2 patients compared to the eighth edition.</p><p><strong>Discussion: </strong>Our study provided validation and endorsement for the revisions implemented in the ninth edition pT staging, specifically the reclassification of patients with fissural invasion from pT1 to pT2. This research contributed to the precise staging of PM patients.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1557097"},"PeriodicalIF":3.5000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457411/pdf/","citationCount":"0","resultStr":"{\"title\":\"External validation of pathological T adjustments in the ninth edition of the pleural mesothelioma tumor-node-metastasis classification.\",\"authors\":\"Zheng Liu, Jingsheng Cai, Yun Li, Wenhan Weng\",\"doi\":\"10.3389/fonc.2025.1557097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In the ninth edition pleural mesothelioma (PM) pathological (p) T staging, patients with fissural invasion are upgraded from T1 to T2. This study aimed to externally validate this staging modification.</p><p><strong>Methods: </strong>Resected pT1/2 PM patients were selected. The Kaplan-Meier method was applied to assess survival differences, and propensity score matching was utilized to balance baseline characteristics. Univariable and multivariable Cox analyses were conducted to determine prognostic factors. Multiple model parameters were used to evaluate the performance of the ninth and eighth edition pT staging in distinguishing between T1 and T2 patients.</p><p><strong>Results: </strong>A total of 818 eligible patients were included, among whom 325 initially classified as T1 were reclassified as T2 due to fissural invasion, resulting in 57 patients remaining with pT1 disease. Survival analyses demonstrated that both before and after matching, the ninth edition T staging effectively differentiated between T1 and T2 patients, whereas the eighth edition did not perform as satisfactorily in distinguishing between the groups. Cox regression analyses further confirmed that the ninth edition T staging was a strong prognostic factor, whereas the eighth edition T staging was not prognostic. Lastly, model parameter results indicated that the ninth edition T staging performed better in distinguishing between T1 and T2 patients compared to the eighth edition.</p><p><strong>Discussion: </strong>Our study provided validation and endorsement for the revisions implemented in the ninth edition pT staging, specifically the reclassification of patients with fissural invasion from pT1 to pT2. This research contributed to the precise staging of PM patients.</p>\",\"PeriodicalId\":12482,\"journal\":{\"name\":\"Frontiers in Oncology\",\"volume\":\"15 \",\"pages\":\"1557097\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12457411/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fonc.2025.1557097\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1557097","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:在第九版胸膜间皮瘤(PM)病理(p) T分期中,有裂隙侵犯的患者由T1升级为T2。本研究旨在从外部验证这种分期改变。方法:选择已切除的pT1/2 PM患者。Kaplan-Meier法用于评估生存差异,倾向评分匹配用于平衡基线特征。进行单变量和多变量Cox分析以确定预后因素。我们使用多个模型参数来评估第九版和第八版pT分期在区分T1和T2患者中的表现。结果:共纳入818例符合条件的患者,其中325例最初为T1的患者因裂陷而被重新分类为T2,导致57例患者保留pT1疾病。生存分析表明,匹配前后,第九版T分期有效区分T1和T2患者,而第八版T分期在区分组间表现不尽如人意。Cox回归分析进一步证实,第9版T分期是一个强有力的预后因素,而第8版T分期则不是预后因素。最后,模型参数结果表明,与第八版相比,第九版T分期在区分T1和T2患者方面表现更好。讨论:我们的研究为第九版pT分期的修订提供了验证和认可,特别是将裂性侵犯患者从pT1重新分类为pT2。该研究有助于PM患者的精确分期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
External validation of pathological T adjustments in the ninth edition of the pleural mesothelioma tumor-node-metastasis classification.

Introduction: In the ninth edition pleural mesothelioma (PM) pathological (p) T staging, patients with fissural invasion are upgraded from T1 to T2. This study aimed to externally validate this staging modification.

Methods: Resected pT1/2 PM patients were selected. The Kaplan-Meier method was applied to assess survival differences, and propensity score matching was utilized to balance baseline characteristics. Univariable and multivariable Cox analyses were conducted to determine prognostic factors. Multiple model parameters were used to evaluate the performance of the ninth and eighth edition pT staging in distinguishing between T1 and T2 patients.

Results: A total of 818 eligible patients were included, among whom 325 initially classified as T1 were reclassified as T2 due to fissural invasion, resulting in 57 patients remaining with pT1 disease. Survival analyses demonstrated that both before and after matching, the ninth edition T staging effectively differentiated between T1 and T2 patients, whereas the eighth edition did not perform as satisfactorily in distinguishing between the groups. Cox regression analyses further confirmed that the ninth edition T staging was a strong prognostic factor, whereas the eighth edition T staging was not prognostic. Lastly, model parameter results indicated that the ninth edition T staging performed better in distinguishing between T1 and T2 patients compared to the eighth edition.

Discussion: Our study provided validation and endorsement for the revisions implemented in the ninth edition pT staging, specifically the reclassification of patients with fissural invasion from pT1 to pT2. This research contributed to the precise staging of PM patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Frontiers in Oncology
Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
6.20
自引率
10.60%
发文量
6641
审稿时长
14 weeks
期刊介绍: Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信